CURIS, INC. (NASDAQ:CRIS) Files An 8-K Regulation FD Disclosure

Item7.01

From time to time, we conduct meetings with third parties in
which we utilize a corporate slide presentation.A copy of our
current corporate slide presentation, dated December 2016, is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.

The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed Filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

About CURIS, INC. (NASDAQ:CRIS)

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

CURIS, INC. (NASDAQ:CRIS) Recent Trading Information

CURIS, INC. (NASDAQ:CRIS) closed its last trading session up +0.07 at 2.81 with 548,791 shares trading hands.